Successful Remission in Ulcerative Colitis Patients Achieved Using Combination Therapy

Successful Remission in Ulcerative Colitis Patients Achieved Using Combination Therapy
In a new study entitled “Combination Therapy With Adalimumab Plus Intensive Granulocyte and Monocyte Adsorptive Apheresis in Patients With Refractory Ulcerative Colitis,” a team of researchers investigated if a combined therapy of adalimumab with granulocyte and monocyte adsorptive apheresis offers benefits when administered to patients with refractory ulcerative colitis who failed to respond to conventional therapies (corticosteroids, azathioprine, and/or aminosalicylic acid). The study was published in the Journal of Clinical Medicine Research. Patients with moderate to severe ulcerative colitis, a form of inflammatory bowel disease (IBD) that causes inflammation and ulcers in the colon, who failed to achieve clinical remission or respond to conventional therapy, were reported to experience successful results from adalimumab, ADA (a tumor necrosis factor, TNF, inhibiting drug that binds to TNF and prevents TNF-induced inflammation). However, the percentage of patients responding to ADA monotherapy was only 16.5% after 8 weeks of therapy. In this new study, a team of researchers investigated the efficacy of a different therapy called granulocyte and monocyte adsorptive apheresis (GMA) when added to ADA. GMA uses a device that allows the remotion of activated granulocytes and monocytes -- cells known to promote IBD -- from a patient's blood. The blood, free of these particular cells, is then returned to the patient. The team performed a retrospective analysis of a 10-week therapy combining ADA plus intens
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *